instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Progressive multifocal leukoencephalopathy'? | Early Pathological JC Virus Lesions in a Patient without Any MRI-based Indications.
A 70-year-old woman with a human T-cell leukemia virus type 1 infection without any focal neurological symptoms showed age-related atherosclerotic changes in the white matter without any suspicious signal changes suggestive of progressi... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33162483 | 19,962,956 | 2021-04-15 |
What is the weight of the patient? | Coronary Artery Spasm During Catheter Ablation Caused by the Intravenous Infusion of Isoproterenol.
Radiofrequency ablation is an established treatment for atrial fibrillation (AF). However, coronary artery spasm (CAS) is a rare but a potentially lethal complication associated with this procedure. A 54-year-old man wit... | 90.4 kg. | Weight | CC BY-NC-ND | 33162486 | 18,549,615 | 2021-04-15 |
What was the administration route of drug 'ISOPROTERENOL HYDROCHLORIDE'? | Coronary Artery Spasm During Catheter Ablation Caused by the Intravenous Infusion of Isoproterenol.
Radiofrequency ablation is an established treatment for atrial fibrillation (AF). However, coronary artery spasm (CAS) is a rare but a potentially lethal complication associated with this procedure. A 54-year-old man wit... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33162486 | 18,549,615 | 2021-04-15 |
What was the administration route of drug 'ISOPROTERENOL'? | Coronary Artery Spasm During Catheter Ablation Caused by the Intravenous Infusion of Isoproterenol.
Radiofrequency ablation is an established treatment for atrial fibrillation (AF). However, coronary artery spasm (CAS) is a rare but a potentially lethal complication associated with this procedure. A 54-year-old man wit... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33162486 | 18,563,630 | 2021-04-15 |
What was the dosage of drug 'ISOPROTERENOL HYDROCHLORIDE'? | Coronary Artery Spasm During Catheter Ablation Caused by the Intravenous Infusion of Isoproterenol.
Radiofrequency ablation is an established treatment for atrial fibrillation (AF). However, coronary artery spasm (CAS) is a rare but a potentially lethal complication associated with this procedure. A 54-year-old man wit... | 5 µg (micrograms). | DrugDosage | CC BY-NC-ND | 33162486 | 18,549,615 | 2021-04-15 |
What was the outcome of reaction 'Arteriospasm coronary'? | Coronary Artery Spasm During Catheter Ablation Caused by the Intravenous Infusion of Isoproterenol.
Radiofrequency ablation is an established treatment for atrial fibrillation (AF). However, coronary artery spasm (CAS) is a rare but a potentially lethal complication associated with this procedure. A 54-year-old man wit... | Recovered | ReactionOutcome | CC BY-NC-ND | 33162486 | 18,563,630 | 2021-04-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'No adverse event'. | Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic.
Pharmacogenetic (PGx) testing is a tool to identify patients at a higher risk of adverse events or treatment failure. The concern for unwanted side effects can limit medication adherence, particularly in child... | ARIPIPRAZOLE | DrugsGivenReaction | CC BY-NC-ND | 33166056 | 19,918,322 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arrhythmia'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atrioventricular block'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest pain'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocardial ischaemia'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Syncope'. | Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards an... | CARFILZOMIB | DrugsGivenReaction | CC BY | 33169938 | 18,544,063 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | BISMUTH, METRONIDAZOLE, OMEPRAZOLE, TETRACYCLINE | DrugsGivenReaction | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | BISMUTH SUBCITRATE POTASSIUM\METRONIDAZOLE\TETRACYCLINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33176617 | 18,518,449 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | BISMUTH SUBCITRATE POTASSIUM\METRONIDAZOLE\TETRACYCLINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33176617 | 18,518,445 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypocalcaemia'. | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | BISMUTH SUBCITRATE POTASSIUM\METRONIDAZOLE\TETRACYCLINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33176617 | 18,518,449 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | BISMUTH, METRONIDAZOLE, OMEPRAZOLE, TETRACYCLINE | DrugsGivenReaction | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | BISMUTH, METRONIDAZOLE, OMEPRAZOLE, TETRACYCLINE | DrugsGivenReaction | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
What was the dosage of drug 'BISMUTH SUBCITRATE POTASSIUM\METRONIDAZOLE\TETRACYCLINE HYDROCHLORIDE'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | UNK, QID | DrugDosageText | CC BY-NC-ND | 33176617 | 18,518,449 | 2021-02 |
What was the dosage of drug 'METRONIDAZOLE'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | UNK (EVERY 6 HOURS FOR 10 DAYS) | DrugDosageText | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
What was the dosage of drug 'OMEPRAZOLE'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | UNK (EVERY 6 HOURS FOR 10 DAYS) | DrugDosageText | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
What was the dosage of drug 'TETRACYCLINE'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | UNK (EVERY 6 HOURS FOR 10 DAYS) | DrugDosageText | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
What was the outcome of reaction 'Abdominal pain'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | Recovered | ReactionOutcome | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
What was the outcome of reaction 'Condition aggravated'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | Recovered | ReactionOutcome | CC BY-NC-ND | 33176617 | 18,518,449 | 2021-02 |
What was the outcome of reaction 'Hypertension'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | Recovered | ReactionOutcome | CC BY-NC-ND | 33176617 | 18,518,445 | 2021-02 |
What was the outcome of reaction 'Hypocalcaemia'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | Recovered | ReactionOutcome | CC BY-NC-ND | 33176617 | 18,518,449 | 2021-02 |
What was the outcome of reaction 'Nausea'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | Recovered | ReactionOutcome | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
What was the outcome of reaction 'Vomiting'? | European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks... | Recovered | ReactionOutcome | CC BY-NC-ND | 33176617 | 20,009,914 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epithelioid mesothelioma'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal disorder'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to bone'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to liver'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to lung'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to spine'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tumour pain'. | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | EVEROLIMUS, SORAFENIB | DrugsGivenReaction | CC BY | 33180365 | 19,513,964 | 2021-01 |
What was the outcome of reaction 'Epithelioid mesothelioma'? | TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of ... | Fatal | ReactionOutcome | CC BY | 33180365 | 19,513,964 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anxiety'. | Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department.
OBJECTIVE
To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital.
METHODS
We collected the patient records of 1600 emergency room visits of a univers... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33188450 | 19,623,452 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cholecystitis acute'. | Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department.
OBJECTIVE
To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital.
METHODS
We collected the patient records of 1600 emergency room visits of a univers... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33188450 | 19,623,452 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperhidrosis'. | Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department.
OBJECTIVE
To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital.
METHODS
We collected the patient records of 1600 emergency room visits of a univers... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33188450 | 19,623,452 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department.
OBJECTIVE
To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital.
METHODS
We collected the patient records of 1600 emergency room visits of a univers... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33188450 | 19,623,452 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tremor'. | Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department.
OBJECTIVE
To investigate the characteristics of ADRs in patients admitting at the emergency room of a tertiary hospital.
METHODS
We collected the patient records of 1600 emergency room visits of a univers... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33188450 | 19,623,452 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ascites'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,620,249 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug-induced liver injury'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,570,215 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic fibrosis'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic haemorrhage'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic lymphocytic infiltration'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic necrosis'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatitis chronic active'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection reactivation'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,620,249 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Liver injury'. | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PREDNISOLONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
What was the administration route of drug 'CYCLOPHOSPHAMIDE'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33191319 | 18,570,215 | 2021-05-15 |
What was the administration route of drug 'DOXORUBICIN HYDROCHLORIDE'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33191319 | 18,570,215 | 2021-05-15 |
What was the administration route of drug 'PREDNISOLONE'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33191319 | 18,570,215 | 2021-05-15 |
What was the administration route of drug 'RITUXIMAB'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33191319 | 18,570,215 | 2021-05-15 |
What was the administration route of drug 'VINCRISTINE'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33191319 | 18,570,215 | 2021-05-15 |
What was the dosage of drug 'VINCRISTINE SULFATE'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | R?CHOP REGIMEN | DrugDosageText | CC BY-NC-ND | 33191319 | 18,609,070 | 2021-05-15 |
What was the outcome of reaction 'Ascites'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Fatal | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,620,249 | 2021-05-15 |
What was the outcome of reaction 'Febrile neutropenia'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,687,039 | 2021-05-15 |
What was the outcome of reaction 'Hepatic failure'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Fatal | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,687,039 | 2021-05-15 |
What was the outcome of reaction 'Hepatic fibrosis'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
What was the outcome of reaction 'Hepatic haemorrhage'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
What was the outcome of reaction 'Hepatic lymphocytic infiltration'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
What was the outcome of reaction 'Hepatic necrosis'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
What was the outcome of reaction 'Hepatitis chronic active'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
What was the outcome of reaction 'Infection reactivation'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Fatal | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,620,249 | 2021-05-15 |
What was the outcome of reaction 'Liver injury'? | Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.
A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunc... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33191319 | 18,608,123 | 2021-05-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aortitis'. | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, FAMOTIDINE, FUROSEMIDE, GRANISETRON HYDROCHLORIDE, IFOSFAMIDE, MESNA, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chemotherapy'. | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, FAMOTIDINE, FUROSEMIDE, GRANISETRON HYDROCHLORIDE, IFOSFAMIDE, MESNA, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hidradenitis'. | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33191326 | 18,682,768 | 2021-04-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, FAMOTIDINE, FUROSEMIDE, GRANISETRON HYDROCHLORIDE, IFOSFAMIDE, MESNA, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, FAMOTIDINE, FUROSEMIDE, GRANISETRON HYDROCHLORIDE, IFOSFAMIDE, MESNA, PEGFILGRASTIM | DrugsGivenReaction | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
What is the weight of the patient? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | 69.4 kg. | Weight | CC BY-NC-ND | 33191326 | 18,682,768 | 2021-04-15 |
What was the administration route of drug 'DOXORUBICIN HYDROCHLORIDE'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
What was the administration route of drug 'IFOSFAMIDE'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
What was the administration route of drug 'MESNA'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
What was the administration route of drug 'PEGFILGRASTIM'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
What was the outcome of reaction 'Aortitis'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Recovered | ReactionOutcome | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
What was the outcome of reaction 'Hidradenitis'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Recovered | ReactionOutcome | CC BY-NC-ND | 33191326 | 18,682,768 | 2021-04-15 |
What was the outcome of reaction 'Rash'? | Granulocyte Colony-stimulating Factor-induced Aortitis with Lung Injury, Splenomegaly, and a Rash During Treatment for Recurrent Extraosseous Mucinous Chondrosarcoma.
We herein report a case of aortitis induced by granulocyte colony-stimulating factor (G-CSF) that coincided with lung injury, splenomegaly, and cutaneous... | Recovered | ReactionOutcome | CC BY-NC-ND | 33191326 | 17,433,107 | 2021-04-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | IRINOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33191588 | 18,565,485 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intestinal obstruction'. | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | IRINOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33191588 | 18,565,477 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | IRINOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33191588 | 18,565,465 | 2021-02 |
What was the administration route of drug 'IRINOTECAN HYDROCHLORIDE'? | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33191588 | 18,565,477 | 2021-02 |
What was the dosage of drug 'IRINOTECAN HYDROCHLORIDE'? | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | 90?MINUTE IV INFUSION, EVERY 3 WEEKS | DrugDosageText | CC BY-NC-ND | 33191588 | 18,565,485 | 2021-02 |
What was the outcome of reaction 'Febrile neutropenia'? | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | Fatal | ReactionOutcome | CC BY-NC-ND | 33191588 | 18,565,485 | 2021-02 |
What was the outcome of reaction 'Intestinal obstruction'? | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | Fatal | ReactionOutcome | CC BY-NC-ND | 33191588 | 18,565,477 | 2021-02 |
What was the outcome of reaction 'Neutropenia'? | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with ep... | Fatal | ReactionOutcome | CC BY-NC-ND | 33191588 | 18,565,465 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood 1,25-dihydroxycholecalciferol increased'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood 25-hydroxycholecalciferol decreased'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood alkaline phosphatase increased'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood parathyroid hormone decreased'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | CALCIUM CITRATE, CALCIUM GLUCONATE, POTASSIUM PHOSPHATE\SODIUM PHOSPHATE, SODIUM PHOSPHATE | DrugsGivenReaction | CC BY | 33191899 | 19,139,574 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood parathyroid hormone increased'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood phosphorus increased'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | CALCIUM CITRATE, CALCIUM GLUCONATE, POTASSIUM PHOSPHATE\SODIUM PHOSPHATE, SODIUM PHOSPHATE | DrugsGivenReaction | CC BY | 33191899 | 19,139,574 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Breast cancer metastatic'. | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by factor-induced dysregulation of phosphate and vitamin D metabolism resulting in alterations in bone formation, leading to bone pain and frac... | DENOSUMAB, NIVOLUMAB, PACLITAXEL, PALBOCICLIB, ZOLEDRONIC ACID | DrugsGivenReaction | CC BY | 33191899 | 17,820,365 | 2021-02 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.